An MBP antagonist
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Myelin Basic Protein Peptide Antagonist (trifluoroacetate salt)

Item No. 36964

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
L-α-glutamyl-L-lysyl-L-prolyl-L-lysyl-L-valyl-L-α-glutamyl-L-alanyl-L-tyrosyl-L-lysyl-L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-prolyl-L-alanine, trifluoroacetate salt
Synonyms
  • EKPKVEAYKAAAAPA-OH
  • MBP Peptide Antagonist
Molecular Formula
C70H114N18O21 • XCF3COOH
Formula Weight
1543.8
Purity
≥98%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
DMF: 1 mg/mlDMSO: 3 mg/mlEthanol: insolPBS (pH 7.2): 5 mg/ml
SMILES
OC(C(F)(F)F)=O.O=C(O)CC[C@H](N[H])C(N[C@@H](CCCCN[H])C(N1CCC[C@H]1C(N[C@@H](CCCCN[H])C(N[C@@H](C(C)C)C(N[C@@H](CCC(O)=O)C(N[C@H](C(N[C@@H](CC2=CC=C(O)C=C2)C(N[C@@H](CCCCN[H])C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N3CCC[C@H]3C(N[C@H](C(O)=O)C)=O)=O)C)=O)C)=O)C)=O)C)=O)=O)=O)C)=O)=O)=O)=O)=O)=O
InChi Code
InChI=1S/C70H114N18O21.C2HF3O2/c1-36(2)55(86-63(101)47(18-10-13-31-72)82-66(104)52-21-16-34-88(52)69(107)49(19-11-14-32-73)84-60(98)45(74)26-28-53(90)91)67(105)83-48(27-29-54(92)93)62(100)78-40(6)59(97)85-50(35-43-22-24-44(89)25-23-43)64(102)81-46(17-9-12-30-71)61(99)77-39(5)57(95)75-37(3)56(94)76-38(4)58(96)79-41(7)68(106)87-33-15-20-51(87)65(103)80-42(8)70(108)109;3-2(4,5)1(6)7/h22-25,36-42,45-52,55,89H,9-21,26-35,71-74H2,1-8H3,(H,75,95)(H,76,94)(H,77,99)(H,78,100)(H,79,96)(H,80,103)(H,81,102)(H,82,104)(H,83,105)(H,84,98)(H,85,97)(H,86,101)(H,90,91)(H,92,93)(H,108,109);(H,6,7)/t37-,38-,39-,40-,41-,42-,45-,46-,47-,48-,49-,50-,51-,52-,55-;/m0./s1
InChi Key
JHPGEXWNFDTTLX-RMOYKTNBSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $32

    Add

    5 mg

    $141

    Add

    10 mg

    $248

    Add

    25 mg

    $542

    Add
    Product Description

    Myelin basic protein (MBP) peptide antagonist is a synthetic peptide antagonist against the multiple sclerosis (MS) autoantigen MBP.1 MBP peptide antagonist binds to the immunomodulatory region of MBP, corresponding to residues 85-99 and inhibits MBP binding to human HLA-DR2 in a concentration-dependent manner. It inhibits the production of IL-2 in T cell hybridoma cells expressing an MBP (85-99)-specific T cell receptor derived from a patient with multiple sclerosis. MBP peptide antagonist also delays MBP (85-99)-induced experimental autoimmune encephalomyelitis (EAE) onset and reduces EAE symptom severity in double-transgenic humanized mice expressing human HLA-DR2 and MBP (85-99)-specific T cell receptor antigen in a model of MS when administered at a dose of 100 µg/animal.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Stern, J.N.H., Illés, Z., Reddy, J., et al. Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 102(5), 1620-1625 (2005).